Obstructive sleep apnoea (OSA) is common and is associated with many vascular risk factors, such as hypertension, insulin resistance, albuminuria, dyslipidaemia, increased inflammation and endothelial dysfunction. Epidemiological studies have shown that OSA is associated with increased cardiovascular disease (CVD) and that continuous positive airway pressure (CPAP) might reduce CVD events in patients with OSA. In addition, OSA has also been shown to be associated with albuminuria, chronic kidney disease, a wide range of ocular diseases and peripheral neuropathy. Considering that CVD and microvascular complications are major contributors to the morbidity, mortality and the economic burden of diabetes and that OSA is common in patients with type 2 diabetes (T2D), it is important to understand the role of OSA in the development and/or progression of vascular disease in patients with T2D and to explore the impact of CPAP on diabetes-related vascular outcomes. The purpose of this article is to review the evidence for the relationship and impact of OSA on vascular disease and vascular risk factors particularly in patients with T2D.
Type 2 diabetes, obstructive sleep apnoea, vascular disease, vascular risk
Abd A Tahrani is a clinician scientist supported by the National Institute for Health Research (NIHR) in the UK. The views expressed in this publication are those
of the author and not necessarily those of the National Health Service, the NIHR or the Department of Health. No funding was received for the publication of this article.
This article is published under the Creative Commons Attribution Noncommercial License, which permits any non-commercial use, distribution, adaptation
and reproduction provided the original author(s) and source are given appropriate credit.
July 01, 2015 Accepted
July 10, 2015
Abd A Tahrani, Department of Diabetes and Endocrinology, Birmingham Heartlands Hospital, Birmingham B9 5SS, UK. E: Abd.Tahrani@nhs.net
Diabetes-related macro- and microvascular complications contribute significantly to the increased morbidity, mortality, worsened quality of life and social and financial burden observed in patients with diabetes.1–5 Hence, reducing the development and/or the progression of these complications is one of the main aims of treatment in patients with diabetes.
Over the last 2 decades, strategies resulting in the improvements of glycaemic control, blood pressure (BP) and lipids and the use of renin angiotensin aldosterone inhibitors, resulted in reductions in cardiovascular disease (CVD) in patients with diabetes, but there was little impact on diabetic microvascular complications.6 Nonetheless, both CVD and microvascular complications remain common and a better understanding of the pathogenesis of these complications is needed in order to identify new treatment strategies.
Obstructive sleep apnoea (OSA) is common in patients with type 2 diabetes (T2D) (up to 86 % prevalence), which is not surprising considering that increasing age and obesity are common risk factors to both conditions.7,8 OSA is characterised by upper airway instability during sleep that results in recurrent upper airway obstruction resulting in either complete or partial cessation of airflow (i.e. apnoea and hypopnoea, respectively).9 The recurrent obstructions of the upper airway usually result in recurrent oxygen desaturations/re-saturations, cyclical changes in intrathoracic pressure (as the patient attempts to breath against a blocked airway) and recurrent micro arousals that cause sleep fragmentation and reduction in slow wave and rapid eye movement (REM) sleep and result in termination of the apnoea/hypopnoea episodes.9
Several large epidemiological studies and randomised controlled trials (RCTs) have shown that OSA was associated with CVD and CVD risk factors in general populations, while the impact of OSA on vascular disease in patients with T2D has only gained attention in the last few years.7,10,11 In this article the evidence of the relationship and impact of OSA on vascular disease and CVD risk factors will be reviewed, particularly in patients with T2D.
Obstructive Sleep Apnoea and Vascular Risk Factors Obstructive Sleep Apnoea and Hypertension
1. Quality of life in type 2 diabetic patients is affected by
complications but not by intensive policies to improve
blood glucose or blood pressure control (UKPDS 37),
U.K. prospective diabetes study group, Diabetes Care,
2. de Groot M, Anderson R, Freedland KE, et al., Association
of depression and diabetes complications: A meta-analysis,
Psychosom Med, 2001;63:619–30.
3. Jacobson AM. Impact of improved glycemic control on quality
of life in patients with diabetes, Endocr Pract, 2004;10:502–8.
4. Al-Maskari F, El-Sadig M, Nagelkerke N, Assessment of the
direct medical costs of diabetes mellitus and its complications
in the United Arab Emirates, BMC Public Health, 2010;10:679.
5. Wang W, Fu CW, Pan CY, et al., How do type 2 diabetes
mellitus-related chronic complications impact direct medical
cost in four major cities of urban China? Value Health,
6. Gregg EW, Li Y, Wang J, et al., Changes in Diabetes-Related
Complications in the United States, 1990–2010, N Engl J Med,
7. Tahrani AA, Ali A, Stevens MJ, Obstructive sleep apnoea and
diabetes: an update, Curr Opin Pulm Med, 2013;19:631–8.
8. Tahrani AA, Ali A, Obstructive sleep apnoea and type 2
diabetes, European Endocrinology, 2014;10:43–50.
9. McNicholas WT, Diagnosis of obstructive sleep apnea in
adults, Proc Am Thorac Soc, 2008;5:154–60.
10. Altaf QA, Barnett AH, Tahrani AA, Novel therapeutics for
type 2 diabetes: insulin resistance, Diabetes Obes Metab,
11. Tahrani AA, Diabetes and sleep apnea. In: International
Textbook of Diabetes Mellitus. Chichester, UK: John Wiley &
Sons Ltd, 2015;316–36.
12. Nieto FJ, Young TB, Lind BK, et al., Association of sleepdisordered
breathing, sleep apnea, and hypertension in a
large community-based study, JAMA, 2000;283:1829–36.
13. Peppard PE, Young T, Palta M, Skatrud J, Prospective study
of the association between sleep-disordered breathing and
hypertension, N Engl J Med, 2000;342:1378–84.
14. Hla KM, Young T, Finn L, et al., Longitudinal association of
sleep-disordered breathing and nondipping of nocturnal
blood pressure in the Wisconsin Sleep Cohort Study, Sleep,
15. Hu X, Fan J, Chen S, et al., The role of continuous positive
airway pressure in blood pressure control for patients with
obstructive sleep apnea and hypertension: A meta-analysis of
randomized controlled trials, J Clin Hypertens, 2015;17:215–22.
16. Andrén A, Hedberg P, Walker-Engström ML, et al., Effects
of treatment with oral appliance on 24-h blood pressure in
patients with obstructive sleep apnea and hypertension: a
randomized clinical trial, Sleep Breath, 2013;17:705–12.
17. Pedrosa RP, Drager LF, de Paula LKG, et al., Effects of osa
treatment on bp in patients with resistant hypertension: A
randomized trial, Chest, 2013;144:1487–94.
18. Martínez-García M, Capote F, Campos-Rodríguez F, Effect of
cpap on blood pressure in patients with obstructive sleep
apnea and resistant hypertension: The hiparco randomized
clinical trial, JAMA, 2013;310:2407–15.
19. Muxfeldt ES, Margallo V, Costa LMS, et al., Effects of
continuous positive airway pressure treatment on clinic and
ambulatory blood pressures in patients with obstructive sleep
apnea and resistant hypertension: A randomized controlled
trial, Hypertension, 2015;65:736–42.
20. Lloberes P, Sampol G, Espinel E, et al., A randomized
controlled study of CPAP effect on plasma aldosterone
concentration in patients with resistant hypertension and
obstructive sleep apnea, J Hypertens, 2014;32:1650–7
21. Pépin JL, Tamisier R, Barone-Rochette G, et al., Comparison
of continuous positive airway pressure and valsartan in
hypertensive patients with sleep apnea, Am J Respir Crit Care
22. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Effect
of continuous positive airway pressure on the incidence
of hypertension and cardiovascular events in nonsleepy
patients with obstructive sleep apnea: A randomized
controlled trial, JAMA, 2012;307:2161–8.
23. Ayala DE, Moyá A, Crespo JJ, et al., Circadian pattern of
ambulatory blood pressure in hypertensive patients with and
without type 2 diabetes, Chronobiol Int, 2012;30:99–115.
24. Prasad B, Carley DW, Krishnan JA, et al., Effects of
positive airway pressure treatment on clinical measures
of hypertension and type 2 diabetes, J Clin Sleep Med,
25. Myhill PC, Davis WA, Peters KE, et al., Effect of continuous
positive airway pressure therapy on cardiovascular risk
factors in patients with type 2 diabetes and obstructive sleep
apnea, J Clin Endocrinol Metab, 2012;97:4212–8.
26. Stumvoll M, Goldstein BJ, van Haeften TW, Type 2 diabetes:
principles of pathogenesis and therapy, Lancet,
27. Howard G, O’Leary DH, Zaccaro D, et al., Insulin sensitivity and
atherosclerosis, Circulation, 1996;93:1809–17.
28. DeFronzo RA, Ferrannini E, Insulin resistance: a multifaceted
syndrome responsible for NIDDM, obesity, hypertension,
dyslipidemia, and atherosclerotic cardiovascular disease,
Diabetes Care, 1991;14:173–94.
29. Roberts AC, Porter KE, Cellular and molecular mechanisms
of endothelial dysfunction in diabetes, Diabetes and Vascular
Disease Research, 2013;10(6):472–482.
30. Muniyappa R, Sowers JR, Role of insulin resistance in
endothelial dysfunction, Reviews in Endocrine and Metabolic
31. Ginsberg HN, Insulin resistance and cardiovascular disease,
Rev Endocr Metab Disord, 2000;106:453–8.
32. Lambert GW, Straznicky NE, Lambert EA, et al., Sympathetic
nervous activation in obesity and the metabolic syndromecauses,
consequences and therapeutic implications,
Pharmacol Ther, 2010;126:159–72.
33. Pamidi S, Wroblewski K, Broussard J, et al., Obstructive sleep
apnea in young lean men: Impact on insulin sensitivity and
secretion, Diabetes Care, 2012;35:2384–9.
34. Lin QC, Zhang XB, Chen GP, et al., Obstructive sleep apnea
syndrome is associated with some components of metabolic
syndrome in nonobese adults, Sleep Breath, 2012;16:571–8.
35. Lindberg E, Theorell-Haglöw J, Svensson M, et al., Sleep
apnea and glucose metabolism: A long-term follow-up in a
community-based sample, Chest, 2012;142:935–42.
36. Yang D, Liu Z, Yang H, Luo Q, Effects of continuous positive
airway pressure on glycemic control and insulin resistance in
patients with obstructive sleep apnea: a meta-analysis, Sleep
37. Iftikhar IH, Khan MF, Das A, Magalang UJ, Meta-analysis:
Continuous positive airway pressure improves insulin
resistance in patients with sleep apnea without diabetes,
Annals ATS, 2013;10:115–20.
38. Iftikhar IH, Hoyos CM, Phillips CL, Magalang UJ, Meta-analyses
of the association of sleep apnea with insulin resistance, and
the effects of CPAP on HOMA-IR, Adiponectin, and Visceral
adipose fat, J Clin Sleep Med, 2015;11:475–85.
39. Yang D, Liu Z, Yang H, The impact of effective continuous
positive airway pressure on homeostasis model assessment
insulin resistance in non-diabetic patients with moderate to
severe obstructive sleep apnea, Diabetes Metab Res Rev,
40. Hermans MP, Ahn SA, Rousseau MF, Cardiometabolic
phenotype and UKPDS risk in male type 2 diabetic patients
with obstructive sleep apnoea, Diabetes Metab Res Rev,
41. Hermans MP, Ahn SA, Mahadeb YP, Rousseau MF, Sleep apnoea
syndrome and 10-year cardiovascular risk in females with
type 2 diabetes: relationship with insulin secretion and insulin
resistance, Diabetes Metab Res Rev, 2013;29:227–34.
42. Chen L, Pei JH, Chen HM, Effects of continuous positive
airway pressure treatment on glycaemic control and insulin
sensitivity in patients with obstructive sleep apnoea and type
2 diabetes: a meta-analysis, Arch Med Sci, 2014;10:637–42.
43. Harsch IA, Schahin SP, Brückner K, et al., The effect of
continuous positive airway pressure treatment on insulin
sensitivity in patients with obstructive sleep apnoea
syndrome and type 2 diabetes, Respiration, 2004;71:252–9.
44. Brooks BELI, Cistulli PA, Borkman M, et al., Obstructive sleep
apnea in obese noninsulin-dependent diabetic patients:
effect of continuous positive airway pressure treatment on
insulin responsiveness, JCEM, 1994;79:1681–5.
45. Nadeem R, Singh M, Nida M, et al., Effect of obstructive sleep
apnea hypopnea syndrome on lipid profile: A meta-regression
analysis, J Clin Sleep Med, 2014;10:475–89.
46. Adedayo A, Olafiranye O, Smith D, et al., Obstructive
sleep apnea and dyslipidemia: evidence and underlying
mechanism, Sleep Breath, 2014;18:13–8.
47. Nadeem R, Singh M, Nida M, et al., Effect of cpap treatment
for obstructive sleep apnea hypopnea syndrome on lipid
profile: A Meta-Regression Analysis, J Clin Sleep Med,
48. Xu H, Yi H, Guan J, Yin S, Effect of continuous positive airway
pressure on lipid profile in patients with obstructive sleep
apnea syndrome: A meta-analysis of randomized controlled
trials, Atherosclerosis, 2014;234:446–53.
49. Jullian-Desayes I, Joyeux-Faure M, Tamisier R, et al., Impact
of obstructive sleep apnea treatment by continuous positive
airway pressure on cardiometabolic biomarkers: A systematic
review from sham CPAP randomized controlled trials, Sleep
Medicine Reviews, 2015;21:23–38.
50. Greenberg H, Ye X, Wilson D, et al., Chronic intermittent
hypoxia activates nuclear factor-kB in cardiovascular tissues
in vivo, Biochem Biophys Res Commun, 2006;343:591–
51. Toffoli S, Feron O, Raes M, Michiels C, Intermittent hypoxia
changes HIF-1α phosphorylation pattern in endothelial cells:
Unravelling of a new PKA-dependent regulation of HIF-1α,
Biochimica et Biophysica Acta, 2007;1773:1558–71.
52. Alberti A, Sarchielli P, Gallinella E, et al., Plasma cytokine
levels in patients with obstructive sleep apnea syndrome: a
preliminary study, J Sleep Res, 2003;12:305–11.
53. Liu H, Liu J, Xiong S, et al., The change of interleukin-6 and
tumor necrosis factor in patients with obstructive sleep
apnea syndrome, J Tongji Med Univ, 2000;20(3):200–2.
54. Vgontzas AN, Papanicolaou DA, Bixler EO, et al., Sleep apnea
and daytime sleepiness and fatigue: Relation to visceral
obesity, insulin resistance, and hypercytokinemia, J Clin
Endocrinol Metab, 2000;85:1151–8.
55. Ciftci TU, Kokturk O, Bukan N, Bilgihan A, The relationship
between serum cytokine levels with obesity and obstructive
sleep apnea syndrome, Cytokine, 2004;28:87–91.
56. Bravo ML, Serpero L, Barcelo A, et al., Inflammatory proteins
in patients with obstructive sleep apnea with and without
daytime sleepiness, Sleep Breath, 2007;11(3):177–85.
57. Minoguchi K, Yokoe T, Tazaki T, et al., Increased carotid
intima-media thickness and serum inflammatory markers
in obstructive sleep apnea, Am J Respir Crit Care Med,
58. Hayashi M, Fujimoto K, Urushibata K, et al., Hypoxiasensitive
molecules may modulate the development of
atherosclerosis in sleep apnoea syndrome, Respirology,
59. Arnardottir ES, Mackiewicz M, Gislason T, et al., Molecular
signatures of obstructive sleep apnea in adults: a review and
perspective, Sleep, 2009;32:447–
60. Ursavas A, Karadag M, Rodoplu E, et al., Circulating ICAM-1
and VCAM-1 levels in patients with obstructive sleep apnea
syndrome, Respiration, 2007;74:525–32.
61. Ohga E, Tomita T, Wada H, et al., Effects of obstructive sleep
apnea on circulating ICAM-1, IL-8, and MCP-1, J Appl Physiol,
62. Sharma SK, Mishra HK, Sharma H, et al., Obesity, and not
obstructive sleep apnea, is responsible for increased serum
hs-CRP levels in patients with sleep-disordered breathing in
Delhi, Sleep Medicine, 2008;9:149–56.
63. Imagawa S, Yamaguchi Y, Ogawa K, et al., Interleukin-6 and
tumor necrosis factor-alpha in patients with obstructive sleep
apnea-hypopnea syndrome. Respiration, 2004;71:24–9.
64. Tahrani A, Ali A, Oxidative stress, inflammation and
endothelial dysfunction: The link between obstructive sleep
apnoea and vascular disease in type 2 diabetes. In: Obrosova
I, Stevens MJ, Yorek MA, editors, Studies in Diabetes, Springer
New York, 2014;149–71.
65. Nadeem R, Molnar J, Madbouly EM, et al., Serum
inflammatory markers in obstructive sleep apnea: a metaanalysis,
J Clin Sleep Med, 2013;9:1003–12.
66. Stradling JR, Craig SE, Kohler M, et al., Markers of
inflammation: data from the MOSAIC randomised trial of CPAP
for minimally symptomatic OSA, Thorax, 2015;70:181–2.
67. Dyugovskaya L, Lavie P, Lavie L, Lymphocyte activation as
a possible measure of atherosclerotic risk in patients with
sleep apnea, Ann N Y Acad Sci, 2005;1051:340–50.
68. Dyugovskaya L, Lavie P, Hirsh M, Lavie L, Activated CD8+
T-lymphocytes in obstructive sleep apnoea, Eur Respir J,
69. Dyugovskaya L, Polyakov A, Lavie P, Lavie L, Delayed
neutrophil apoptosis in patients with sleep apnea, Am J
Respir Crit Care Med, 2008;177:544–54.
70. Dyugovskaya L, Lavie P, Lavie L, Increased adhesion
molecules expression and production of reactive oxygen
species in leukocytes of sleep apnea patients, Am J Respir
Crit Care Med, 2002;165:934–9.
71. Lavie L, Dyugovskaya L, Polyakov A, Biology of peripheral
blood cells in obstructive sleep apnea–the tip of the iceberg,
Arch Physiol Biochem 2008;114:244–54.
72. Lavie L, Oxidative stress inflammation and endothelial
dysfunction in obstructive sleep apnea, Front Biosci (Elite Ed),
73. Schulz R, Mahmoudi S, Hattar K, et al., Enhanced release
of superoxide from polymorphonuclear neutrophils in
obstructive sleep apnea. Impact of continuous positive
airway pressure therapy, Am J Respir Crit Care Med,
2000;162(2 Pt 1):566–
74. Dyugovskaya L, Polyakov A, Cohen-Kaplan V, et al., Bax/Mcl-1
balance affects neutrophil survival in intermittent hypoxia
and obstructive sleep apnea: effects of p38MAPK and ERK1/2
signaling, J Transl Med, 2012;10:211.
75. Zamarron-Sanz C, Ricoy-Galbaldon J, Gude-Sampedro F,
Riveiro-Riveiro A, Plasma levels of vascular endothelial
markers in obstructive sleep apnea, Arch Med Res,
76. Chin K, Nakamura T, Shimizu K, et al., Effects of nasal
continuous positive airway pressure on soluble cell
adhesion molecules in patients with obstructive sleep apnea
syndrome, Am J Med, 2000;109:562–7.
77. Minoguchi K, Yokoe T, Tazaki T, et al., Silent brain infarction
and platelet activation in obstructive sleep apnea, Am J
Respir Crit Care Med, 2007;175:612–
78. Schulz R, Schmidt D, Blum A, et al., Decreased plasma levels
of nitric oxide derivatives in obstructive sleep apnoea:
response to CPAP therapy, Thorax, 2000;55:1046–51.
79. Ip MS, Lam B, Chan LY, et al., Circulating nitric oxide is
suppressed in obstructive sleep apnea and is reversed by
nasal continuous positive airway pressure, Am J Respir Crit
Care Med, 2000;162:2166–71.
80. Jelic S, Padeletti M, Kawut SM, et al., Inflammation, Oxidative
stress, and repair capacity of the vascular endothelium in
obstructive sleep apnea, Circulation, 2008;117:2270–8.
81. Ohike Y, Kozaki K, Iijima K, et al., Amelioration of vascular
endothelial dysfunction in obstructive sleep apnea syndrome
by nasal continuous positive airway pressure–possible
involvement of nitric oxide and asymmetric NG, NGdimethylarginine,
Circ J, 2005;69:221–6.
82. Yim-Yeh S, Rahangdale S, Nguyen ATD, et al., Vascular
dysfunction in obstructive sleep apnea and type 2 diabetes
mellitus, Obesity, 2011;19:17–22.
83. Carlson JT, Rångemark C, Hedner JA, Attenuated endotheliumdependent
vascular relaxation in patients with sleep apnoea,
J Hypertens, 1996;14:577–84.
84. Kato M, Roberts-Thomson P, Phillips BG, et al., Impairment
of endothelium-dependent vasodilation of resistance
vessels in patients with obstructive sleep apnea, Circulation,
85. Nieto FJ, Herrington DM, Redline S, et al., Sleep apnea
and markers of vascular endothelial function in a large
community sample of older adults, Am J Respir Crit Care
86. Tahrani AA, Ali A, Raymond NT, et al., Obstructive sleep
apnea and diabetic neuropathy: a novel association in
patients with type 2 diabetes, Am J Respir Crit Care Med,
87. Young T, Peppard PE, Gottlieb DJ, Epidemiology of obstructive
sleep apnea: A population health perspective, Am J Respir
Crit Care Med, 2002;165:1217–39.
88. Martinez D, Klein C, Rahmeier L, et al., Sleep apnea is a
stronger predictor for coronary heart disease than traditional
risk factors, Sleep Breath, 2012;16:695–701.
89. Turmel J, Sériès F, Boulet LP, et al., Relationship between
atherosclerosis and the sleep apnea syndrome: An
intravascular ultrasound study, Int J Cardiol, 2009;132:203–9.
90. Kent BD, Garvey JF, Ryan S, et al., Severity of obstructive sleep
apnoea predicts coronary artery plaque burden: a coronary
CT angiography study, Eur Respir J, 2013;42:1263–70.
91. Sert Kuniyoshi FH, Garcia-Touchard A, Gami AS, et al., Daynight
variation of acute myocardial infarction in obstructive
sleep apnea, J Am Coll Cardiol, 2008;52:343–6.
92. Peker Y, Hedner J, Norum J, et al., Increased incidence of
cardiovascular disease in middle-aged men with obstructive
sleep apnea: A 7-year follow-up, Am J Respir Crit Care Med,
93. Marin JM, Carrizo SJ, Vicente E, Agusti AG, Long-term
cardiovascular outcomes in men with obstructive sleep
apnoea-hypopnoea with or without treatment with
continuous positive airway pressure: An observational study,
94. Yaggi HK, Concato J, Kernan WN, et al., Obstructive sleep
apnea as a risk factor for stroke and death, New Engl J Med,
95. Ou Q, Chen YC, Zhuo SQ, et al., Continuous positive airway
pressure treatment reduces mortality in elderly patients with
moderate to severe obstructive severe sleep apnea: A cohort
study, PLoS ONE, 2015;10:e0127775.
96. Molnar MZ, Mucsi I, Novak M, et al., Association of incident
obstructive sleep apnoea with outcomes in a large cohort of
US veterans, Thorax, 2015 [Epub ahead of print].
97. Gottlieb DJ, Yenokyan G, Newman AB, et al., Prospective
study of obstructive sleep apnea and incident coronary
heart disease and heart failure: The sleep heart health study,
98. Arzt M, Young T, Finn L, et al., Association of sleep-disordered
breathing and the occurrence of stroke, Am J Respir Crit Care
99. Redline S, Yenokyan G, Gottlieb DJ, et al., Obstructive sleep
apnea-hypopnea and incident stroke, Am J Respir Crit Care
100. Campos-Rodriguez F, Martinez-Garcia MA, Reyes-Nuñez N,
et al., Role of sleep apnea and continuous positive airway
pressure therapy in the incidence of stroke or coronary
heart disease in women, Am J Respir Crit Care Med,
101. Rice TB, Foster GD, Sanders MH, et al., The relationship
between obstructive sleep apnea and self-reported stroke or
coronary heart disease in overweight and obese adults with
type 2 diabetes mellitus, Sleep, 2012;35:1293–8.
102. Seicean S, Strohl KP, Seicean A, et al., Sleep disordered
breathing as a risk of cardiac events in subjects with
diabetes mellitus and normal exercise echocardiographic
findings, Am J Cardiol, 2013;111:1214–20.
103. Kimmel PL, Miller G, Mendelson WB, Sleep apnea syndrome in
chronic renal disease, Am J Med, 1989;86:308–14.
104. Unruh ML, Sanders MH, Redline S, et al., Sleep apnea in
patients on conventional thrice-weekly hemodialysis:
comparison with matched controls from the sleep heart
health study, J Am Soc Nephrol, 2006;17:3503–9.
105. Wadhwa NK, Seliger M, Greenberg HE, et al., Sleep related
respiratory disorders in end-stage renal disease patients on
peritoneal dialysis, Perit Dial Int, 1992;12:51–6.
106. Hanly PJ, Ahmed SB, Sleep apnea and the kidney: Is sleep
apnea a risk factor for chronic kidney disease?, Chest,
107. Prejbisz A, Florczak E, Pregowska-Chwala B, et al.,
Relationship between obstructive sleep apnea and markers
of cardiovascular alterations in never-treated hypertensive
patients, Hypertens Res, 2014;37:573–9.
108. Chou YT, Lee PH, Yang CT, et al., Obstructive sleep apnea:
a stand-alone risk factor for chronic kidney disease,
Nephrology Dialysis Transplantation, 2011;26:2244–50.
109. Canales M, Paudel M, Taylor B, et al., Sleep-disordered
breathing and urinary albumin excretion in older men,
Sleep Breath, 2011;15:137–44.
110. Faulx MD, Storfer-Isser A, Kirchner HL, et al., Obstructive sleep
apnea is associated with increased urinary albumin excretion,
111. Tsioufis C, Thomopoulos C, Dimitriadis K, et al., Association
of obstructive sleep apnea with urinary albumin excretion in
essential hypertension: a cross-sectional study, Am J Kidney
112. Agrawal V, Vanhecke TE, Rai B, et al., Albuminuria and renal
function in obese adults evaluated for obstructive sleep
apnea, Nephron Clin Pract, 2009;113:c140–c147.
113. Casserly LF, Chow N, Ali S, et al., Proteinuria in obstructive
sleep apnea, Kidney Int, 2001;60:1484–9.
114. Mello P, Franger M, Boujaoude Z, et al., Night and day
proteinuria in patients with sleep apnea, Am J Kidney Dis,
115. Canales MT, Taylor BC, Ishani A, et al., Reduced renal function
and sleep-disordered breathing in community-dwelling
elderly men, Sleep Med, 2008;9:637–45.
116. Canales MT, Lui LY, Taylor BC, et al., Renal function and sleepdisordered
breathing in older men, Nephrol Dial Transplant,
117. Sakaguchi Y, Shoji T, Kawabata H, et al., High prevalence
of obstructive sleep apnea and its association with renal
function among nondialysis chronic kidney disease patients
in japan: A cross-sectional study, Clin J Am Soc Nephrol,
118. Ahmed SB, Ronksley PE, Hemmelgarn BR, et al.,
Nocturnal hypoxia and loss of kidney function, PLoS ONE,
119. Yasar ZA, Ucar ZZ, Demir AU, et al., Does CPAP therapy alter
urinary albumin level in adult patients with moderate to
severe obstructive sleep apnea syndrome? Sleep Breath,
120. Comondore V, Cheema R, Fox J, et al., The impact of CPAP on
cardiovascular biomarkers in minimally symptomatic patients
with obstructive sleep apnea: A pilot feasibility randomized
crossover trial, Lung, 2009;187:17–22.
121. Zhang XB, Jiang XT, Lin QC, et al., Effect of continuous positive
airway pressure on serum cystatin C among obstructivesleep
apnea syndrome patients, Int Urol Nephrol, 2014;46:1997–2002.
122. Koga S, Ikeda S, Yasunaga T, et al., Effects of nasal continuous
positive airway pressure on the glomerular filtration rate in
patients with obstructive sleep apnea syndrome, Int Med,
123. Tahrani AA, Ali A, Raymond NT, et al., Obstructive sleep apnea
and diabetic nephropathy: A cohort study. Diabetes Care,
124. Furukawa S, Saito I, Yamamoto S, et al., Nocturnal intermittent
hypoxia as an associated risk factor for microalbuminuria
in Japanese patients with type 2 diabetes mellitus, Eur J
125. Buyukaydin B, Akkoyunlu ME, Kazancioglu R, et al., The
effect of sleep apnea syndrome on the development of
diabetic nephropathy in patients with type 2 diabetes,
Eur J Endocrinol, 2012;98:140–3.
126. Leong WB, Nolen M, Thomas GN, et al., The impact of
hypoxemia on nephropathy in extremely obese patients with
type 2 diabetes mellitus, J Clin Sleep Med, 2014;10:773–8.
127. Boland LL, Shahar E, Wong TY, et al., Sleep-disordered
breathing is not associated with the presence of retinal
microvascular abnormalities: The sleep heart health study,
128. Kloos P, Laube I, Thoelen A, Obstructive sleep apnea in
patients with central serous chorioretinopathy, Graefes Arch
Clin Exp Ophthalmol, 2008;246:1225–8.
129. Leveque TK, Yu L, Musch DC, et al., Central serous
chorioretinopathy and risk for obstructive sleep apnea,
Sleep Breath, 2007;11:253–7.
130. Karakucuk S, Goktas S, Aksu M, et al., Ocular blood flow in
patients with obstructive sleep apnea syndrome (OSAS),
Graefes Arch Clin Exp Ophthalmol, 2008;246:129–34.
131. Leroux Les JG, Glacet-Bernard A, Lasry S, et al., [Retinal vein
occlusion and obstructive sleep apnea syndrome.], J Fr
132. Brodie FL, Charlson ES, Aleman TS, et al., Obstructive
sleep apnea and central serous chorioretinopathy, Retina,
133. Ferrandez B, Ferreras A, Calvo P, et al., Retinal sensitivity is
reduced in patients with obstructive sleep apneaobstructive
sleep apnea and visual field, Invest Ophthalmol Vis Sci,
134. Shiba T, Takahashi M, Sato Y, et al., Relationship between
severity of obstructive sleep apnea syndrome and retinal
nerve fiber layer thickness, Am J Ophthalmol,
135. Shiba T, Maeno T, Saishin Y, et al., nocturnal intermittent
serious hypoxia and reoxygenation in proliferative diabetic
retinopathy cases, Am J Ophthalmol, 2010;149:959–63.
136. West SD, Groves DC, Lipinski HJ, et al., The prevalence of
retinopathy in men with Type 2 diabetes and obstructive
sleep apnoea, Diabet Med, 2010;27:423–30.
137. Tahrani AA, Dodson P, Ali A, et al., Obstructive sleep apnoea
is associated with sight threatening retinopathy and predicts
the development of preproliferative and proliferative
retinopathy in patients with type 2 diabetes: a longitudinal
analysis, Eur J Ophthalmol, 2013;23:449.
138. Nishimura A, Kasai T, Tamura H, et al., Relationship between
sleep disordered breathing and diabetic retinopathy: Analysis
of 136 patients with diabetes, Diabetes Res Clin Pract, 2015
[Epub ahead of print].
139. Banerjee D, Leong WB, Arora T, et al., The potential association
between obstructive sleep apnea and diabetic retinopathy
in severe obesity—The role of hypoxemia, PLoS ONE,
140. Nesmith BL, Ihnen M, Schaal S, Poor responders to
bevacizumab pharmacotherapy in age-related macular
degeneration and in diabetic macular edema demonstrate
increased risk for obstructive sleep apnea, Retina,
141. Mason RH, Kiire CA, Groves DC, et al., Visual improvement
following continuous positive airway pressure therapy in
diabetic subjects with clinically significant macular oedema
and obstructive sleep apnoea: Proof of principle study,
142. Mayer P, Dematteis M, Pepin JL, et al., Peripheral neuropathy
in sleep apnea. A tissue marker of the severity of nocturnal
desaturation, Am J Respir Crit Care Med, 1999;159:213–9.
143. Ludemann P, Dziewas R, Soros P, et al., Axonal
polyneuropathy in obstructive sleep apnoea,
J Neurol Neurosurg Psychiatry, 2001;70:685–7.
144. Dziewas R, Schilling M, Engel P, et al., Treatment for
obstructive sleep apnoea: Effect on peripheral nerve function,
J Neurol Neurosurg Psychiatry, 2007;78:295–7.
145. Ma RC-W, So WY, Yang X, et al., Erectile dysfunction predicts
coronary heart disease in type 2 diabetes, J Am Coll Cardiol,
146. Inman BA, Sauver JLS, Jacobson DJ, et al., A population-based,
longitudinal study of erectile dysfunction and future coronary
artery disease, Mayo Clinic Proceedings, 2009;84:108–13.
147. Hoyos CM, Melehan KL, Phillips CL, et al., To ED or not
to ED-Is erectile dysfunction in obstructive sleep apnea
related to endothelial dysfunction? Sleep Medicine Reviews,
148. Li F, Feng Q, Zhang X, Liu Q, [Treatment for erectile
dysfunction patients with obstructive sleep apnea syndrome
by nasal continual positive airway pressure], Zhonghua nan
ke xue=National Journal of Andrology, 2004;10:355–7.
149. Perimenis P, Karkoulias K, Markou S, et al., Erectile
dysfunction in men with obstructive sleep apnea syndrome: a
randomized study of the efficacy of sildenafil and continuous
positive airway pressure, Int J Impot Res, 2004;16:256–60.
150. Perimenis P, Karkoulias K, Konstantinopoulos A, et al.,
Sildenafil versus continuous positive airway pressure for
erectile dysfunction in men with obstructive sleep apnea:
a comparative study of their efficacy and safety and the
patient’s satisfaction with treatment, Asian J Androl,
151. Li X, Dong Z, Wan Y, Wang Z, Sildenafil versus continuous
positive airway pressure for erectile dysfunction in men
with obstructive sleep apnea: a meta-analysis, Aging Male,
152. Knapp A, Myhill PC, Davis WA, et al., Effect of continuous
positive airway pressure therapy on sexual function and
serum testosterone in males with type 2 diabetes and
obstructive sleep apnoea, Clin Endocrinol, 2014;81:254–8.
153. Lacasse Y, Godbout C, Sèriés F. Health-related quality of life in
obstructive sleep apnoea, Eur Respir J, 2002;19:499–503.
154. Akashiba T, Kawahara S, Akahoshi T, et al., Relationship
between quality of life and mood or depression in patients
with severe obstructive sleep apnea syndrome*, Chest,
155. Appleton S, Vakulin A, McEvoy RD, et al., Undiagnosed
obstructive sleep apnea is independently associated with
reductions in quality of life in middle-aged, but not elderly
men of a population cohort, Sleep Breath, 2015;1–8.
156. D’Ambrosio C, Bowman T, Mohsenin V, Quality of life in
patients with obstructive sleep apnea*: Effect of nasal
continuous positive airway pressure—a prospective study,
157. Diamanti C, Manali E, Ginieri-Coccossis M, et al., Depression,
physical activity, energy consumption, and quality of life in
OSA patients before and after CPAP treatment, Sleep Breath,
158. Bjornsdottir E, Keenan BT, Eysteinsdottir B, et al., Quality of
life among untreated sleep apnea patients compared with
the general population and changes after treatment with
positive airway pressure, J Sleep Res, 2015;24:328–38.
Type 2 diabetes, obstructive sleep apnoea, vascular disease, vascular risk